This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Cubist Stops Enrollment In Anti-bleeding Studies

MARLEY SEAMAN

NEW YORK (AP) ¿ Cubist Pharmaceuticals Inc. said Thursday it stopped enrolling patients in trials of a drug intended to reduce bleeding during heart surgery because of deaths among patients that took it.

Cubist said a data monitoring board wants to assess the difference between patients on the drug, and those who were on an alternative treatment. Overall, the rate of deaths in the studies was consistent with expected outcomes, and the causes of death were typical for a group of patients that was at a high risk for bleeding during cardiac surgery, Cubist said.

The monitors suggested Cubist suspend enrollment in a study that compared the experimental drug to Cyklokapron, a drug that is approved in Europe to control bleeding. Cubist decided to stop enrolling patients in that study, and in a second study that compared its drug to a placebo.

The news battered shares of Dyax Corp., which discovered the compound and licensed it to Cubist. The drug is Dyax's lead product candidate, and in afternoon trading, shares of the Cambridge, Mass., company lost 29 cents, or 6.9 percent, to $3.94.

The drug was called ecallantide, but Cubist is now designating it as CB-500,929.

Cubist said it had enrolled more than 450 patients in the two studies, which were called CONSERV-1 and CONSERV-2. It planned for about 650 patients. The Lexington, Mass., company plans to continue collecting data on patients who were already treated and analyze the results.

CB-500,929 is intended for use in "on-pump" surgeries, or operations in which a patient's heart is stopped, and blood is kept flowing with a cardiopulmonary bypass machine. Such operations include coronary artery bypass graft surgeries and heart valve replacements and repairs.

Following an analyst upgrade, Cubist shares rose 76 cents, or 4.4 percent, to $18.05.

Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
CBST $101.94 0.14%
DYAX $16.76 0.00%
AAPL $124.43 0.00%
FB $82.22 0.00%
GOOG $548.00 0.00%

Markets

DOW 17,776.12 -200.19 -1.11%
S&P 500 2,067.89 -18.35 -0.88%
NASDAQ 4,900.8850 -46.5560 -0.94%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs